Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection

NCT04421027 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT04421027
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04421027 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase 3 Study of Baricitinib in Patients With COVID-19 Infection
Lead sponsor
Eli Lilly and Company
Phase
Phase 3
Overall status
Completed
Start date
June 12, 2020
Completion date
June 10, 2021
Enrollment
1,525 (actual)
Sites
96

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19